Foghorn Therapeutics Inc. (FHTX) Tops Q3 EPS by 12c

Foghorn Therapeutics Inc. (NASDAQ: FHTX) reported Q3 EPS of ($0.31), $0.12 better than the analyst estimate of ($0.43). Revenue for the quarter came in at $7.81 million versus the consensus estimate of $6.34 million.

For earnings history and earnings-related data on Foghorn Therapeutics Inc. (FHTX) click here.

You May Also Be Interested In

• Bessent: We Make A Market Buying Older Bonds
• B.Riley Reiterates Buy Rating on IonQ, Inc. (IONQ)
• Intel (INTC) call put ratio 2.5 calls to 1 put with a focus on October 2 weekly calls as share price up 7.8%